- Home
- PTCT vs TGTX Comparison
PTCT vs TGTX Comparison
Compare PTCT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTCT
- TGTX
- Stock Information
- Founded
- PTCT 1998
- TGTX 1993
- Country
- PTCT United States
- TGTX United States
- Employees
- PTCT N/A
- TGTX 264
- Industry
- PTCT Biotechnology: Pharmaceutical Preparations
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- PTCT Health Care
- TGTX Health Care
- Exchange
- PTCT Nasdaq
- TGTX Nasdaq
- Market Cap
- PTCT N/A
- TGTX 5.4B
- IPO Year
- PTCT 2013
- TGTX 1995
- Fundamental
- Price
- PTCT $42.89
- TGTX $34.55
- Analyst Decision
- PTCT Hold
- TGTX Strong Buy
- Analyst Count
- PTCT 12
- TGTX 6
- Target Price
- PTCT $42.58
- TGTX $37.67
- AVG Volume (30 Days)
- PTCT 743.9K
- TGTX 4.4M
- Earning Date
- PTCT 11-07-2024
- TGTX 11-04-2024
- Dividend Yield
- PTCT N/A
- TGTX N/A
- EPS Growth
- PTCT N/A
- TGTX N/A
- EPS
- PTCT N/A
- TGTX N/A
- Revenue
- PTCT $900,664,000.00
- TGTX $264,790,000.00
- Revenue This Year
- PTCT N/A
- TGTX $43.74
- Revenue Next Year
- PTCT N/A
- TGTX $64.30
- P/E Ratio
- PTCT N/A
- TGTX N/A
- Revenue Growth
- PTCT 12.84
- TGTX 39.53
- 52 Week Low
- PTCT $20.75
- TGTX $12.30
- 52 Week High
- PTCT $46.98
- TGTX $36.50
- Technical
- Relative Strength Index (RSI)
- PTCT 57.17
- TGTX 68.82
- Support Level
- PTCT $38.26
- TGTX $28.59
- Resistance Level
- PTCT $45.65
- TGTX $36.50
- Average True Range (ATR)
- PTCT 2.20
- TGTX 2.67
- MACD
- PTCT -0.31
- TGTX 0.34
- Stochastic Oscillator
- PTCT 53.10
- TGTX 85.64
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.